OTC Markets OTCQB - Delayed Quote USD

Emmaus Life Sciences, Inc. (EMMA)

0.0155

0.0000

(0.00%)

At close: April 10 at 4:00:00 PM EDT

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its Endari® (L-glutamine oral powder) has been afforded market exclusivity in the Kingdom of Saudi Arabia, or KSA, by the National Uniform Procurement Agency, or NUPCO (NUPCO Tender No. 014/24 COMPLIMENTARY PHARMA TENDER January 09, 2025). NUPCO, KSA's unified purchasing system, extends to all KSA government institutions, including hospit

PR Newswire 2 months ago

EMMA
0.00%
Emmaus Life Sciences Reports Improved Quarterly Financial Results

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.

PR Newswire 4 months ago

EMMA
0.00%
Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.

PR Newswire 6 months ago

EMMA
0.00%
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer

Emmaus Life Sciences, Inc. (OTCMarkets: EMMA), a leader in sickle cell disease treatment, announced that Willis C. Lee has been appointed as Chief Executive Officer. Mr. Lee, who previously served as Co-President and Chief Operating Officer, will continue to serve as Chairman of the Board.

PR Newswire 8 months ago

EMMA
0.00%
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.

PR Newswire 8 months ago

EMMA
0.00%
Emmaus Life Sciences Reports 2023 Financial Results

Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2023.

PR Newswire 9 months ago

EMMA
0.00%
Emmaus Life Sciences Reports Delayed Filing of Annual Report

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

PR Newswire 11 months ago

EMMA
0.00%

Performance Overview

Return	EMMA	S&P 500 (^GSPC)
YTD	+82.35%	-8.81%
1-Year	-85.24%	+3.16%
3-Year	-97.93%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Emmaus Life Sciences, Inc. (EMMA)

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

Emmaus Life Sciences Reports Improved Quarterly Financial Results

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer

Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Emmaus Life Sciences Reports 2023 Financial Results

Emmaus Life Sciences Reports Delayed Filing of Annual Report

Performance Overview